tbuckley/cabot-search huggingface dataset:
Immunology of Cultivated Mammalian Cells. II. The Effect of Heterophil Hemagglutinin Content of Serum for Cultivation of Mammalian Cells&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: K. Gerhard Brand, M.D.
Journal: JNCI Journal of the National Cancer Institute (1960)

Pools of “normal” calf serum varied in capacity to agglutinate human and rabbit erythrocytes; some high-titer serums were relatively toxic for growth of human and rabbit cells in continuous culture and for maintenance of human cells in primary culture. Serum toxicity for human and rabbit cells was non-specifically reduced by absorption with human or rabbit erythrocytes. Lysed erythrocytes of either species added to calf serum improved its quality for cultivation of human and rabbit cells but did not inhibit comparably its capacity to agglutinate erythrocytes. Toxicity of the calf serum notably was decreased in the presence of unheated, compared to inactivated, guinea-pig serum. Neither the ability of calf and guinea-pig serums to agglutinate human and rabbit erythrocytes nor the toxicity of calf serum for cell cultures was reduced appreciably by absorption with human or rabbit culture cells.
EPIG-07PROGNOSTIC ROLE OF HISTONE H3 LYSINE 27 DEMETHYLASE (UTX) AND HISTONE H3 LYSINE 4 METHYLTRANSFERASE (MLL4) ON THE GLIOBLASTOMA PATIENTS WITH METHYLATED MGMT PROMOTER
Authors: Jinho Kim, Ji Hwan Jang, Young Min Lee, Eun Hee Lee, Sung-Hun Lee, Young Zoon Kim
Journal: Neuro-Oncology (2015)

OBJECTIVE: This study was undertaken primarily to investigate the epigenetic and prognostic role of H3K4 methyltransferase (MLL4) and H3K27 demethylase (UTX) in PFS and OS of glioblastoma patients who were treated with radiotherapy and/or chemotherapy after surgical resection. METHODS: The medical records of 76 patients with glioblastoma newly diagnosed and histologically proven from January 2002 to December 2013 at our hospital were reviewed retrospectively. Immunohistochemical staining was performed on archived paraffin-embedded tissues obtained by surgical resection for MLL4 and UTX. The methylation status of MGMT promoter was determined retrospectively by MS-PCR analysis. RESULTS: During follow-up period (mean duration of 27.5 months, ranged from 4.1 to 43.5 months), 68 patients (89.5%) died. MGMT promoter was methylated in 49 patients (64.5%) and unmethylated in 27 (35.5%). In terms of immunoreactivity of UTX-MLL4 complex, overexpression was found in 42 samples (55.3%) and underexpression in 34 samples (44.7%). Median PFS was 9.2 months (95% confidence interval [CI] of 6.8-11.6 months). Extent of surgery and methylation status of MGMT promoter was associated with PFS in multivariate analysis of factors predicting PFS. Median OS was 18.6 months (95% CI of 16.3-20.9 months). Age of patients (p = 0.004), performance status (p < 0.05), extent of surgery (p < 0.05), RPA class (p < 0.05), methylation status of MGMT promoter (p = 0.010), and immunoreactivity of UTX-MLL4 complex (p = 0.001) were associated with OS in multivariate analysis of factors predicting OS. Interestingly, in the patients with unmethylated MGMT promoter, immunoreactivity of UTX-MLL4 complex was not associated with OS (p = 0.350). However, in the patients with methylated MGMT promoter, immunoreactivity was strongly associated with OS (p < 0.001). Even patients with underexpression of UTX-MLL4 complex did not have statistical difference in OS between methylated MGMT promoter (p = 0.589) and unmethylated MGMT promoter (p = 0.838). CONCLUSION: This study suggests that overexpression of UTX-MLL4 complex should influence on the better outcome of glioblastoma patients with methylated MGMT promoter.
Factors Predicting Intentional Non-Adherence In Chronic Myeloid Leukemia: A Multivariate Analysis On 2546 Patients By The CML Advocates Network
Authors: Jan Geissler, Fabio Efficace, Felice Bombaci, Jan de Jong, Anthony Michael Gavin, Euzebiusz J Dziwinski, Mina Daban, Jana Pelouchová, Francesco Cottone, Joelle Guilhot, Giora Sharf
Journal: Blood (2013)
After Bypass Surgery
Authors: Henry Langhorne
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgical adjuvant treatment of large bowel cancer.
Authors: C G Moertel
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.6.934 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3373264 Surgical adjuvant treatment of large bowel cancer. C G MoertelxC G MoertelSearch for articles by this author Show More Mayo Clinic, Rochester, MN. https://doi.org/10.1200/JCO.1988.6.6.934 First Page PDF © 1988 by American Society of Clinical Oncology
Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study
Authors: Valeria Magarotto, Sara Bringhen, Pellegrino Musto, Massimo Offidani, Anna Marina Liberati, Ludek Pour, Giulia Benevolo, Mariella Genuardi, Caterina Musolino, Antonio Ledda, Daniela Oddolo, Lorenzo De Paoli, Francesca Patriarca, Antonietta Pia Falcone, Isola Caratozzolo, Renato Zambello, Maide Cavalli, Silvia Gentili, Roman Hajek, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2014)
Testicular perfusion scintigraphy
Authors: Q. H. Siraj
Journal: Clinical Nuclear Medicine (1998)

The use of perfusion scintigraphy in the evaluation of acute scrotal disease, particularly for reliable and accurate diagnosis of testicular torsion, has been the most widely employed clinical application of radionuclide testicular imaging. Scintigraphic evaluation of testicular perfusion in a patient presenting with an acute hemi-scrotum is one of the few emergency nuclear medicine procedures which has a significant impact on clinical decision making and patient management.
EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Authors: Olli Carpen, Annika Ålgars, Jari Sundström, Soili Kytölä, Pia Österlund, Minnamaija Lintunen, Terhi Jokilehto, Milja Kaare, Arto Orpana, Reetta Vainionpää, Ari Ristimäki, Raija Ristamäki
Journal: Journal of Clinical Oncology (2016)

e15108 Background: Anti-EGFR monoclonal antibodies are used for the treatment of RAS wild type (wt) metastatic colorectal cancer. However, only a fraction of patients selected for treatment by the RAS mutation status benefit. We previously showed that EGFR gene copy number (GCN), as analyzed by immunohistochemistry (IHC)-guided in situ hybridization (ISH), predicts response to anti-EGFR therapy in KRAS exon 2 wild-type (wt) metastatic colorectal cancer. The aim of this study was to analyze the predictive role of EGFR GCN in RAS/BRAF/PIK3CA wt metastatic colorectal cancer. Methods: The patient material included 102 patients with KRAS exon 2 wt metastatic colorectal cancer treated with anti-EGFR antibodies. Next generation sequencing (NGS) was used for KRAS exons 2, 3 and 4, NRAS exons 2, 3 and 4, BRAF and PIK3CA gene mutation analyses from primary tumor tissue samples. EGFR GCN was analyzed by EGFR IHC guided automated silver ISH (GCN cutoff 4.0). Results: RAS, BRAF, and PIK3CA gene mutation analyses were successfully performed for 86.3% of the patients. Additional mutations in the RAS gene were found in 28.4% (25/88) of the KRAS exon 2 wt tumors. BRAF and PIK3CA mutations were observed in 22.7% and 15.9% of the cases, respectively. EGFR GCN was ≥ 4.0 in a majority of the RAS wt patients (40/63, 63.5%). An elevated EGFR GCN predicted a better response to anti-EGFR therapy and prolonged PFS in the RAS/BRAF/PIK3CA wt patients. In addition, most RAS wt patients with an EGFR GCN ≥ 4.0 in their primary tumors benefited of anti-EGFR therapy in terms of clinical benefit (SD, PR or CR) (Chi-Square Test, p = 0.0005), and had a longer progression free survival than those with a EGFR GCN below 4.0 (Log-Rank Test, p < 0.0001). In contrast, the response RAS/BRAF/PIK3CA wt, EGFR GCN below 4.0 patients did not differ from patients with mutant in RAS, or BRAF or PIK3CA. Conclusions: The study indicates that EGFR GCN serves as a predictive marker for anti-EGFR treatment efficacy in patients with RAS/BRAF/PIK3CA wtmetastatic colorectal cancer. Tumors with EGFR GCN below 4.0 appear to be as refractory to anti-EGFR treatment as tumors with mutation in any of the RAS/RAF/PIK3CA pathway genes.
Metabolomic analysis of pegylated arginine deiminase treatment in patients with malignant pleural mesothelioma.
Authors: Essam Ahmed Ghazaly, Phuong Luong, Magdalena Chmielewska-Kassassir, Lucyna Wozniak, John S. Bomalaski, John G. Gribben, Peter Wojciech Szlosarek
Journal: Journal of Clinical Oncology (2014)

7587 Background: Arginine is a key amino acid for tumorigenesis modulating a diverse array of metabolic pathways, from synthesis of proteins, NO and polyamines to nucleotide turnover and mTOR signalling. Tumors deficient in the urea cycle enzyme, argininosuccinate synthetase 1 (ASS1), are especially sensitive to deprivation of exogenous arginine using the drug pegylated arginine deiminase (ADI-PEG20, Polaris Group, US). Previously, we have reported the metabolic changes induced by ADI treatment in a panel of ASS1-deficient bladder cancer and malignant pleural mesothelioma (MPM) cell lines. Here, we examined the metabolic effects in plasma of patients with MPM treated with ADI [ClinicalTrials.gov NCT01279967]. Methods: MPM plasma samples (29 patients treated with ADI-PEG20 and 6 control patients over a 9 wk period) were analysed by ultra performance liquid chromatography-mass spectrometry (UPLC-MS) for untargeted identification and quantitation of the metabolomic changes. The top metabolic changes were then assessed by targeted UPLC-MS/MS. Results: ADI-PEG20 induced marked changes in plasma, which clearly discriminated treated from untreated patients using partial least squares discriminant analysis (PLS-DA), a multivariate statistical approach. As expected, the plasma [arginine] decreased (126±15µM wk 0 vs 3.2±2.5 µM wk3) with a reciprocal increase in the plasma [citrulline] (56±6µM wk 0 vs 879±113 µM wk3) in ADI-PEG20 treated patients only. In addition, ADI-PEG20 treatment triggered the following novel plasma metabolite changes: increased [thymine] (3.0±0.4 µM week 0 vs 11.5±1.5 µM wk 3), [carnitine] (43±5 µM week 0 vs 96±7 µM wk 3) and [proline] (147±18 µM wk 0 vs 246±37 µM wk 3), while decreasing [isoleucine] (53±11 µM week 0 vs 17±4 µM wk 3). A 2-fold increase in plasma [glutamine] and [glutamate] was detected in non-responder patients as assessed by PET-CT, reaching a maximum by wk 5 of ADI-PEG20 treatment. Conclusions: This study has identified several metabolic changes in plasma that may be employed as potential biomarkers for optimizing the efficacy of ADI-PEG20 in the treatment of MPM and other arginine-dependent cancers. Clinical trial information: NCT01279967.
Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
Authors: Anthony Mato, Chadi Nabhan, Paul M. Barr, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Alan P Skarbnik, Christina Howlett, Jeffrey J Pu, Alison R. Sehgal, Lauren E. Strelec, Alexandra Vandegrift, Allison Rago, Clive S Zent, Tatyana Feldman, Andre Goy, David F. Claxton, Spencer Henick Bachow, Gurbakhash Kaur, Jakub Svoboda, Sunita Dwivedy Nasta, David Porter, Daniel J. Landsburg, Stephen J. Schuster, Bruce D. Cheson, Andrew M. Evens
Journal: Blood (2015)
Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain
Authors: Phillip O. Coffin, Emily Behar, Christopher Rowe, Glenn-Milo Santos, Diana Coffa, Matthew Bald, Eric Vittinghoff
Journal: Annals of Internal Medicine (2016)

Background: Unintentional overdose involving opioid analgesics is a leading cause of injury-related death in the United States. Objective: To evaluate the feasibility and effect of implementing naloxone prescription to patients prescribed opioids for chronic pain. Design: 2-year nonrandomized intervention study. Setting: 6 safety-net primary care clinics in San Francisco, California. Participants: 1985 adults receiving long-term opioid therapy for pain. Intervention: Providers and clinic staff were trained and supported in naloxone prescribing. Measurements: Outcomes were proportion of patients prescribed naloxone, opioid-related emergency department (ED) visits, and prescribed opioid dose based on chart review. Results: 38.2% of 1985 patients receiving long-term opioids were prescribed naloxone. Patients prescribed higher doses of opioids and with an opioid-related ED visit in the past 12 months were independently more likely to be prescribed naloxone. Patients who received a naloxone prescription had 47% fewer opioid-related ED visits per month in the 6 months after receipt of the prescription (incidence rate ratio [IRR], 0.53 [95% CI, 0.34 to 0.83]; P = 0.005) and 63% fewer visits after 1 year (IRR, 0.37 [CI, 0.22 to 0.64]; P < 0.001) compared with patients who did not receive naloxone. There was no net change over time in opioid dose among those who received naloxone and those who did not (IRR, 1.03 [CI, 0.91 to 1.27]; P = 0.61). Limitation: Results are observational and may not be generalizable beyond safety-net settings. Conclusion: Naloxone can be coprescribed to primary care patients prescribed opioids for pain. When advised to offer naloxone to all patients receiving opioids, providers may prioritize those with established risk factors. Providing naloxone in primary care settings may have ancillary benefits, such as reducing opioid-related adverse events. Primary Funding Source: National Institutes of Health.
Pathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation
Authors: Antonio Cannatà, Luca Camparini, Gianfranco Sinagra, Mauro Giacca, Francesco S. Loffredo
Journal: Cardiovascular Research (2016)

The world population is aging, and by 2017, there will be more people over the age of 65 than under age 5, and by 2050, two billion of the estimated nine billion people on Earth will be older than 60. Aging itself is a major cardiovascular risk factor, affecting morbidity and mortality of the aging population. At the same time, aging increases the likelihood of the presence of other risk factors. The aged myocardium is characterized by several structural and functional progressive changes that impair its ability to respond appropriately to stressful conditions. Although some progress to understand the complex mechanisms that underlie these phenotypic changes, the molecular pathways that determine the balance between aging and rejuvenation in the aged myocardium still remain elusive. In this article, we review molecular mechanisms responsible for the phenotypic changes observed with aging in the heart, providing insight into molecular pathways and pharmacological interventions that may rejuvenate the aged myocardium. A better understanding of these pathways is essential for determining their therapeutic potential in humans, improving the possibility that the increase in life expectancy that we are observing will be accompanied by a parallel increase in healthspan.
Osteoblastic Cells (OBs) and the Hematopoietic Microenvironment: Parathyroid Hormone (PTH) Increases the Notch Ligand Jagged1 (J1) in a Specific Subpopulation of OBs.
Authors: Shaula R. Forsythe, Jonathan M. Weber, Christina A. Christianson, Benjamin J. Gigliotti, Benjamin J. Frisch, Laura M. Calvi
Journal: Blood (2005)
Genetic analysis of a novel splice-site mutation in<i>TMC8</i>reveals the<i>in vivo</i>importance of the transmembrane channel-like domain of<i>TMC8</i>
Authors: T. Miyauchi, T. Nomura, S. Suzuki, M. Takeda, S. Shinkuma, K. Arita, Y. Fujita, H. Shimizu
Journal: British Journal of Dermatology (2016)
Effects of Podophyllin on Mouse Skin. III. A Study of Epidermal Fibrils&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: L S KING
Journal: JNCI Journal of the National Cancer Institute (1949)

Journal Article Effects of Podophyllin on Mouse Skin. III. A Study of Epidermal Fibrils Get access Lester S. King, M. D. Lester S. King, M. D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 3, December 1949, Pages 689–709, https://doi.org/10.1093/jnci/10.3.689 Published: 01 December 1949 Article history Received: 04 October 1949 Published: 01 December 1949
Surgery for Herniated Vertebral Disks
Authors: F T Wetzel
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is Surgical Removal of Every Colonic Polyp Necessary
Authors: L S FIGIEL, S J FIGIEL, F K WIETERSEN
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major
Authors: Juliano L. Fernandes, Sandra R. Loggetto, Monica P. A. Veríssimo, Kleber Y. Fertrin, Giorgio R. Baldanzi, Luciana A. B. Fioravante, Doralice M. Tan, Tatiana Higa, Denise A. Mashima, Antonio Piga, Otavio R. Coelho, Fernando F. Costa, Sara T. Saad
Journal: Blood (2016)
Research in Anesthesiology
Authors: B R Brown, L J Kettel
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Annexin 2 Mediates Plasminogen-Related Recruitment of Neovascular Mural Cells in Lymphoma Angiogenesis.
Authors: Katherine A. Hajjar, Jia Ruan, Guangzhi Sui, Arunkumar B. Deora, Sarah Church, Leona Cohen-Gould, Shahin Rafii, David C. Lyden, Qi Ling
Journal: Blood (2007)
Regulation of release of hepatocyte growth factor from human promyelocytic leukemia cells, HL-60, by 1,25-dihydroxyvitamin D3, 12-O- tetradecanoylphorbol 13-acetate, and dibutyryl cyclic adenosine monophosphate
Authors: M Inaba, H Koyama, M Hino, S Okuno, M Terada, Y Nishizawa, T Nishino, H Morii
Journal: Blood (1993)